Active Ingredient(s): Vemurafenib
FDA Approved: * August 17, 2011
Pharm Company: * HOFFMAN-LA ROCHE
Category: Cancer

Vemurafenib (INN, marketed as Zelboraf) is an inhibitor of the B-Raf enzyme developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma.[1] The name "vemurafenib" comes from V600E mutated BRAF inhibition. Contents 1 Approvals 2 Mechanism of action 2.1 Resistance 3 Clinical trials 3.1 Side effects 4 References 5 Further reading 6 External links Approvals Vemurafenib received FDA approval for the treatment of late-stage... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Zelboraf 240 mg Oral Tablet
NDC: 50242-090
Genentech, Inc.

Popular Topics

Zelboraf/How to combat joint pain

I've been taking Zelboraf for about 2 weeks and have severe joint pain. I'm looking for a way to combat the join...